PMID- 18496563
OWN - NLM
STAT- MEDLINE
DCOM- 20080911
LR  - 20130304
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 22
IP  - 8
DP  - 2008 Aug
TI  - Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid 
      leukaemia.
PG  - 1542-50
LID - 10.1038/leu.2008.107 [doi]
AB  - Therapeutic effects of haematopoietic stem cell transplantation are not limited 
      to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include 
      specific as well as unspecific immune reactions known as graft-versus-leukaemia 
      (GvL) effects. Specific immune reactions are likely to be particularly relevant 
      to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), 
      in which residual cells may remain quiescent and unresponsive to cytotoxic and 
      molecular therapies for long periods of time. Specific GvL effects result from 
      the expression on leukaemic cells of specific tumour-associated antigens (TAAs) 
      in the context of HLA proteins. As human leukocyte antigen (HLA) types vary 
      widely, the development of broadly applicable tumour vaccines will require the 
      identification of multiple TAAs active in different HLA backgrounds. Here, we 
      describe the identification of NM23-H2 as a novel HLA-A32-restricted TAA of CML 
      cells and demonstrate the presence of specifically reactive T cells in a patient 
      5 years after transplantation. As the NM23 proteins are aberrantly expressed in a 
      range of different tumours, our findings suggest potential applications beyond 
      CML and provide a new avenue of investigation into the molecular mechanisms 
      underlying CML.
FAU - Tschiedel, S
AU  - Tschiedel S
AD  - Department of Hematology and Internal Oncology, University of Leipzig, Leipzig, 
      Germany.
FAU - Gentilini, C
AU  - Gentilini C
FAU - Lange, T
AU  - Lange T
FAU - Wolfel, C
AU  - Wolfel C
FAU - Wolfel, T
AU  - Wolfel T
FAU - Lennerz, V
AU  - Lennerz V
FAU - Stevanovic, S
AU  - Stevanovic S
FAU - Rammensee, H-G
AU  - Rammensee HG
FAU - Huber, C
AU  - Huber C
FAU - Cross, M
AU  - Cross M
FAU - Niederwieser, D
AU  - Niederwieser D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080522
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (DNA, Complementary)
RN  - 0 (NM23 Nucleoside Diphosphate Kinases)
RN  - EC 2.7.4.6 (NME2 protein, human)
SB  - IM
MH  - Adult
MH  - Antigen-Presenting Cells/immunology
MH  - DNA, Complementary
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*immunology/surgery
MH  - Male
MH  - NM23 Nucleoside Diphosphate Kinases/genetics/*immunology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - T-Lymphocytes/immunology
EDAT- 2008/05/23 09:00
MHDA- 2008/09/13 09:00
CRDT- 2008/05/23 09:00
PHST- 2008/05/23 09:00 [pubmed]
PHST- 2008/09/13 09:00 [medline]
PHST- 2008/05/23 09:00 [entrez]
AID - leu2008107 [pii]
AID - 10.1038/leu.2008.107 [doi]
PST - ppublish
SO  - Leukemia. 2008 Aug;22(8):1542-50. doi: 10.1038/leu.2008.107. Epub 2008 May 22.